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ABSTRACT
Objective To examine the association of myocardial
infarction and stroke incidence with several commonly
used two drug antihypertensive treatment regimens.
Design Population based case-control study.
Setting Group Health Cooperative, Seattle, WA, USA.
Participants Cases (n=353) were aged 30-79 years, had
pharmacologically treated hypertension, and were
diagnosedwithafirstfatalornon-fatalmyocardialinfarction
or stroke between 1989 and 2005. Controls (n=952) were a
random sample of Group Health members who had
pharmacologically treated hypertension. We excluded
individuals with heart failure, evidence of coronary heart
disease, diabetes, or chronic kidney disease.
Exposures One of three common two drug combinations:
diuretics plus β blockers; diuretics plus calcium channel
blockers; and diuretics plus angiotensin converting
enzyme inhibitors or angiotensin receptor blockers.
Main outcome measures Myocardial infarction or stroke.
ResultsComparedwithusersof diureticsplus βblockers,
users of diuretics plus calcium channel blockers had an
increased risk of myocardial infarction (adjusted odds
ratio(OR)1.98,95%confidenceinterval1.37to2.87)but
not of stroke (OR 1.02, 95% CI 0.63 to 1.64). The risks of
myocardialinfarctionandstrokein usersof diureticsplus
angiotensin converting enzyme inhibitors or angiotensin
receptor blockers were slightly but not significantly lower
than in users of diuretics plus β blockers (myocardial
infarction:OR 0.76, 95% CI0.52to 1.11; stroke: OR 0.71,
95% CI 0.46 to 1.10).
Conclusions In patients with hypertension, diuretics plus
calcium channel blockers were associated with a higher
risk of myocardial infarction than other commontwo drug
treatment regimens. A large trial of second line
antihypertensive treatments in patients already on low
dose diuretics is required to provide a solid basis for
treatment recommendations.
INTRODUCTION
Untreated high blood pressureis strongly associatedwith
myocardial infarction, stroke, and heart failure. The
findings of the Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial (ALLHAT)
suggested that low dose diuretics are superior to calcium
channel blockers and angiotensin converting enzyme
inhibitors as first line treatment for the prevention of
one or more forms of cardiovascular disease in high risk
patients with hypertension.
1 A network meta-analysis
confirmed and extended these findings.
2
On the basis of this evidence, the seventh report
guidelines issued in the United States by the Joint
National Committee on Prevention, Evaluation, and
Treatment of High Blood Pressure recommend the
use of low dose diuretics as first line pharmacological
treatment for uncomplicated high blood pressure.
3 In
England and Wales, the National Institute for Health
andClinicalExcellenceguidelinesrecommendtheuse
of low dose diuretics as a first choice therapy for high
blood pressure in black patients or those aged 55 or
above, and recommend a combination of diuretics
plus angiotensin converting enzyme inhibitors or
angiotensin receptor blockers in patients under
55 years who do not respond to initial treatment.
4
Abouthalfofallpatientswithhypertensionrequirea
second medication to achieve control of blood pres-
sure. In ALLHAT at five years, for instance, 40.7% of
patients randomly allocated to chlorthalidone were
taking at least one other antihypertensive medication.
Othermajorclassesofantihypertensivemedication—β
blockers, calcium channel blockers, angiotensin con-
verting enzyme inhibitors, and angiotensin receptor
blockers—all lower blood pressure.
1256However, the
optimalsecondlineagentforthe preventionofcardio-
vascular disease among patients who are taking low
dose diuretics and who require additional treatment
for blood pressure control is not known. Although a
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group recommended the conduct of a trial to evaluate
the optimal second line treatment for hypertension,
7
no such trial has been performed to date.
Thepurposeofthiscase-controlstudywastoexamine
the association of myocardial infarction and stroke with
several commonly used two drug treatments regimens:
diuretics plus β blockers; diuretics plus angiotensin con-
vertingenzymeinhibitorsorangiotensinreceptorblock-
ers; and diuretics plus calcium channel blockers.
METHODS
Study setting and participants
Participants were identified from patients enrolled in
the Group Health Cooperative, a large health mainte-
nance organisation located in western Washington
state. Although Group Health provides hypertension
treatment guidelines similar to those of the Joint
National Committee on Prevention, Evaluation, and
Treatment of High Blood Pressure, practising physi-
cians are free to choose an antihypertensive treatment
from any of the major drug classes, all of which are
included in the formulary.
Ongoing studies on drug-gene interactions enabled
us to both identify and follow Group Health patients
with hypertension. This includes both patients who
were identified for previous studies
8 as well and new
patients diagnosed with hypertension. Cases were
identified from the Group Health hospitals’ compu-
terised discharge abstracts, the bills for out of plan ser-
vices provided by non-Group Health physicians and
healthcare facilities, and the results of a computerised
match between Group Health enrolment files and the
Washington state death registry. Individuals between
theageof30and79yearswithpharmacologicallytrea-
tedhypertensionanda diagnosisofanincidentfatalor
non-fatal myocardial infarction between January 1989
and December 2005 or a fatal or non-fatal stroke
between July 1989 and December 2005 were included
in the study. Individuals with myocardial infarction or
stroke events that were a complication of a medical
procedure or surgery were not included. Cases’ diag-
noses were validated by medical record reviews as
described elsewhere.
8
Controls were Group Health members who were
pharmacologically treated for hypertension and met
Table 1 |Characteristics of cases and controls receiving various two drug antihypertensive regimens that included a diuretic
Controls (n=952) Cases (n=353)
Diuretics and
β blockers
(n=459)
Diuretics and
calcium channel
blockers (n=174)
Diuretics and angiotensin
converting enzyme
inhibitors or angiotensin
receptor blockers (n=319)
Diuretics and
β blockers
(n=170)
Diuretics and
calcium channel
blockers (n=99)
Diuretics and angiotensin
converting enzyme inhibitors
or angiotensin receptor
blockers (n=84)
Age (mean (SD)) 65.9 (9.9) 66.6 (9.4) 64.5 (9.7) 69.3 (8.5) 66.1 (10.7) 66.6 (9.5)
Gender (% male) 49.50% 50.60% 56.40% 44.1% 48.0% 52.4%
Race (n (%))
Black or African American 19 (4%) 16 (9%) 14 (5%) 9 (5%) 5 (5%) 3 (4%)
White 415 (91%) 152 (88%) 282 (90%) 151 (92%) 89 (93%) 75 (93%)
Other 20 (5%) 5 (3%) 17 (5%) 5 (3%) 2 (2%) 3 (4%)
Time enrolled at Group Health
(years; mean (SD))
20.6 (12.1) 21.2 (11.8) 18.7 (11.9) 22.2 (13.1) 18.7 (12.8) 18.3 (12.0)
Durationofhypertension(years;mean(SD) 11.3 (8.3) 12.9 (8.3) 10.7 (7.8) 12.3 (9.0) 11.4 (8.8) 10.1 (7.8)
Treatedhypertensionatstudyentry(n(%)) 103 (23%) 40 (23%) 90 (28%) 50 (30%) 37 (37%) 25 (30%)
BMI (mean (SD)) 29.8 (6.4) 30.5 (5.7) 30.0 (6.2) 29.1 (5.2) 31.0 (7.4) 29.1 (5.6)
Current smoking (n (%)) 56 (12%) 15 (9%) 35 (11%) 29 (17%) 16 (16%) 18 (21%)
Familyhistoryofmyocardialinfarction(n(%)) 150 (48%) 65 (58%) 96 (47%) 39 (52%) 35 (53%) 19 (51%)
Glucose (mg/dl; mean (SD)) 102 (20) 107 (32) 103 (20) 109 (27) 107 (35) 105 (26)
Total cholesterol (mg/dl; mean (SD)) 228 (39) 231 (47) 226 (45) 238 (42) 237 (43) 232 (47)
Pretreatment systolic blood pressure
(mm Hg; mean (SD))
163 (19) 163 (19) 164 (21) 171 (26) 171 (21) 166 (18)
Most recent systolic blood pressure
(mm Hg; mean (SD))
140 (17) 143 (16) 139 (19) 143 (20) 147 (18) 140 (18)
Most recent diastolic blood pressure
(mm Hg; mean (SD))
81 (10) 82(9) 82 (11) 82 (11) 85 (11) 83 (11)
Most recent systolic blood pressure
≤140 mm Hg (% achieved)
59% 54% 62% 42% 33% 39%
Most recent systolic blood pressure
≤130 mm Hg (% achieved)
37% 21% 36% 22% 15% 27%
Percentages exclude missing data. Percentages may add up to more than 100 owing to rounding. Data were missing from less than 3% of subjects for all variables except BMI (cases: 4%
for β blockers and angiotensin converting enzymes or angiotensin receptor blockers), duration of hypertension (24%, 26%, and 32% for β blockers, calcium channel blockers, and
angiotensin converting enzymes or angiotensin receptor blockers, respectively), pre-treatment systolic blood pressure (controls: 24%, 26%, and 32% for β blockers, calcium channel
blockers, and angiotensin converting enzymes or angiotensin receptor blockers, respectively; cases: 31%, 41%, and 33% for β blockers, calcium channel blockers, and angiotensin
converting enzymes or angiotensin receptor blockers, respectively), family history (controls: 26%, 29%, and 23% for β blockers, calcium channel blockers, and angiotensin converting
enzymes or angiotensin receptor blockers, respectively; cases: 56%, 33%, and 56% for β blockers, calcium channel blockers, and angiotensin converting enzymes or angiotensin receptor
blockers, respectively), and total cholesterol (controls: 9% for β blockers and 10% for calcium channel blockers and angiotensin converting enzymes or angiotensin receptor blockers; cases:
7% for β blockers and 4% for calcium channel blockers).
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experienced either a myocardial infarction or stroke.
Controls were frequency matched to myocardial
infarction cases—the largest case group—by age
(within a decade), sex, and calendar year of the cases’
diagnoses, at a ratio of between 2:1 and 3:1. The case-
control ratio was based on power calculations con-
ducted for a previous study of ours that addressed a
similar question.
8 Given the importance of investigat-
ing the risks and benefits of second line therapy,
7 we
decided to address the question in the setting of a
case-control study without conducting additional
power calculations.
Index date and eligibility
Each participant was assigned an index date. For cases
admitted to hospital, the index date was defined as the
admission date for the first myocardial infarction or
stroke. For out of hospital fatal cases, the index date
was the date of death. The index date for controls was
acomputergeneratedrandomdatewithinthecalendar
year in which they were sampled. Cases and controls
whowereenrolledinthestudyforlessthanoneyearor
who had had fewer than four visits to a Group Health
clinic before their index date were excluded. We also
excluded all cases and controls who had had either a
myocardialinfarctionorstrokebeforetheirindexdate.
Data collection
Data collection comprised a review of the Group
Health ambulatory medical record and a telephone
interview of consenting survivors. Using the Group
Health medical record, trained medical record
abstractors determined eligibility and collected infor-
mationabouttraditionalriskfactorsforcardiovascular
disease such as blood pressure, smoking, angina, dia-
betes,andcholesterol.Onlyinformationabouttheper-
iod before the index date was used. For patients
consenting to telephone interview, we obtained addi-
tional information about risk factors such as smoking
status, physical activity, education, and race. For indi-
vidualswhodidnotcompletethe telephoneinterview,
these data were obtained from the medical record
review.
Data on drug treatment were extracted from the
Group Health pharmacy database, which includes a
record for each prescription dispensed by a Group
Health pharmacy. Each pharmacy record includes
the drug type and dose, quantity dispensed, and the
dosing instructions. When dosing instructions were
missing from the pharmacy data, dosing instructions
wereobtainedfromthemedicalrecords.Todetermine
use of a particular drug at the index date, we searched
the pharmacy data for the prescription immediately
precedingthatdate.If thepatientreceiveda dosesuffi-
cient to last until the index date and assuming at least
80% compliance, that person was considered a user of
the drug at the index date. To minimise potential con-
founding by newly started prescriptions for conditions
thatrequire drugtreatment, a currentuser wasdefined
asan individualwhowas a user at index date aswell as
at 30 and/or 60 days before the index date.
To minimise confounding by indication, we excluded
participants with heart failure or evidence of coronary
heart disease (defined as a history of coronary bypass
surgery, angioplasty, previous myocardial infarction, or
Table 2 |Relative risk of myocardial infarction and stroke in patients receiving various two drug antihypertensive regimens that included a diuretic
Myocardial infarction Stroke
Cases Controls Odds ratio (95% CI) Cases Controls Odds ratio (95% CI)
Minimally adjusted*
Diuretics and β blockers 93 459 Ref 77 459 Ref
Diuretics and calcium channel blockers 68 174 1.93 (1.34 to 2.77) 31 174 1.00 (0.62 to 1.61)
Diuretics and angiotensin converting enzyme inhibitors
or angiotensin receptor blockers
50 319 0.78 (0.53 to 1.13) 34 319 0.71 (0.46 to 1.10)
Fully adjusted† †
Diuretics and β blockers 93 459 Ref 77 459 Ref
Diuretics and calcium channel blockers 68 174 1.98 (1.37 to 2.87) 31 174 1.02 (0.63 to 1.64)
Diuretics and angiotensin converting enzyme inhibitors
or angiotensin receptor blockers
50 319 0.76 (0.52 to 1.11) 34 319 0.71 (0.46 to 1.10)
Thiazides only† †
Diuretics and β blockers 83 434 Ref 65 434 Ref
Diuretics and calcium channel blockers 59 152 2.08 (1.41 to 3.09) 24 152 1.02 (0.60 to 1.75)
Diuretics and angiotensin converting enzyme inhibitors
or angiotensin receptor blockers
45 291 0.81 (0.54 to 1.21) 29 291 0.75 (0.47 to 1.19)
Index year ≥ ≥1994† †
Diuretics and β blockers 67 315 Ref 57 315 Ref
Diuretics and calcium channel blockers 45 113 1.95 (1.24 to 3.08) 23 113 1.10 (0.63 to 1.94)
Diuretics and angiotensin converting enzyme inhibitors
or angiotensin receptor blockers
40 254 0.74 (0.48 to 1.14) 30 254 0.77 (0.47 to 1.24)
*Adjusted for age, sex, and index year.
†Adjusted for age, sex, index year, smoking, and total cholesterol.
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creatininelevel>2mg/dl).Oftheremainingparticipants,
we includedonlythose patientswho were currentlytrea-
ted with one of the three common two drug combina-
tions: diuretics plus β blockers; diuretics plus calcium
channelblockers;anddiureticsplusangiotensinconvert-
ing enzyme inhibitors or angiotensin receptor blockers.
Statistical analysis
Participants were classified according to their treat-
ment as of the index date: (a) diuretics plus β blockers;
(b) diuretics plus calcium channel blockers; and (c)
diuretics plus angiotensin converting enzyme inhibi-
tors or angiotensin receptor blockers. Multiple logistic
regression models were used to determine maximum
likelihood estimates and their associated robust stan-
dard errors, which were then used to compare the
risk of myocardial infarction and stroke among the
threegroups.
9Usersofdiureticsplusβblockersserved
as the reference group. Models were adjusted for the
matchedvariablesage(linear),sex,andindexyear(lin-
ear spline: 1989-1992; 1993-1996; 1997-2000; and
2001-2005),andforotherpossibleconfoundersinclud-
ing smoking status (current v not) and total cholesterol
levels (linear). We divided daily drug doses into low,
medium, or high. The modal daily dose for each gen-
eric drug was classified as “medium,” whereas daily
doses below that amount were classified as “low” and
daily doses above that amount as “high.” Median
values were used for subgroup analyses by age,
serum glucose concentration, pretreatment systolic
blood pressure, treated systolic blood pressure, and
hypertension duration. Chained equations multiple
imputation was used to account for missing data.
10
The analyses were conducted using Intercooled Stata
8.2(StataCorpLP;CollegeStation,TX)andSAS9.1.3
(SAS;Cary,NC).Oddsratio(OR)estimateswereused
to approximate the relative risk.
RESULTS
We identified 1305 patients who used two drug anti-
hypertensive treatment regimens: 211 patients who
had a first myocardial infarction, 142 who had a first
stroke, and 952 controls. Of these 1305 individuals,
629 were treated with diuretics plus β blockers, 273
with diuretics plus calcium channel blockers, and 403
with diuretics plus angiotensin converting enzyme
inhibitorsorangiotensinreceptorblockers.Theexclu-
sionstominimisethechanceofconfoundingbyindica-
tionresultedinastudypopulationatrelativelylowrisk
of cardiovascular disease.
Among controls, those treated with diuretics plus
calcium channel blockers had a longer history of
hypertension, higher recent systolic blood pressure,
and higher glucose levels than patients treated with
diuretics plus β blockers (table 1). Controls treated
with diuretics plus angiotensin converting enzyme
inhibitors or angiotensin receptor blockers were
younger and had been enrolled at Group Health for a
shorter period than those treated with diuretics plus β
blockers. Among cases, those treated with diuretics
plus calcium channel blockers were younger, had
been enrolled at Group Health for a shorter period of
time,andhadahigherBMIandahigherrecentsystolic
blood pressure than cases treated with diuretics plus β
blockers (table 1). Cases treated with diuretics plus
angiotensinconvertingenzymeinhibitorsorangioten-
sin receptor blockers were younger than those treated
with diuretics plus β blockers.
Table 2 compares the relative risks of myocardial
infarction and stroke in patients receiving the three
antihypertensivedrugregimens.Comparedwithtreat-
ment with diuretics plus β blockers, treatment with
diureticsplus calciumchannelblockerswasassociated
with an increased risk of myocardial infarction (OR
1.93, 95% confidence interval 1.34 to 2.77) and
remained so after adjustment for age, sex, index year,
Table 3 |Relative risk of myocardial infarction and stroke in patients receiving different daily doses (low, medium, high) of two drug antihypertensive
regimens that included a diuretic
Myocardial infarction Stroke
Cases Controls Odds ratio (95% CI) Cases Controls Odds ratio (95% CI)
Diuretics and β β blockers
Low dose β blockers 37 164 Ref 23 166 Ref
Medium dose β blockers 36 198 0.74 (0.44 to 1.25) 34 197 1.35 (0.73 to 2.49)
High dose β blockers 20 97 0.86 (0.47 to 1.59) 20 96 1.42 (0.71 to 2.87)
P value, test for trend 0.53 0.29
Diuretics and calcium channel blockers
Low dose calcium channel blockers 21 62 1.53 (0.82 to 2.87) 10 62 1.14 (0.50 to 2.60)
Medium dose calcium channel blockers 24 66 1.81 (0.96 to 3.39) 12 66 1.29 (0.56 to 2.95)
High dose calcium channel blockers 23 46 2.19 (1.12 to 4.27) 9 46 1.41 (0.57 to 3.54)
P value, test for trend 0.34 0.67
Diuretics and angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs)
Low dose ACE inhibitors or ARBs 15 57 1.56 (0.77 to 3.16) 4 58 0.40 (0.11 to 1.43)
Medium dose ACE inhibitors or ARBs 13 107 0.48 (0.23 to 1.01) 10 106 0.52 (0.22 to 1.24)
High dose ACE inhibitors or ARBs 22 155 0.61 (0.34 to 1.10) 20 155 0.91 (0.48 to 1.71)
P value, test for trend 0.06 0.14
Adjusted for age, sex, index year, smoking, and total cholesterol.
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1.37 to 2.87). The two treatment regimens were asso-
ciated with a similar risk of stroke (fully adjusted OR
1.02, 95% CI 0.63 to 1.64). An increase in the risk of
myocardialinfarctionwasalsoobservedwhendiuretic
therapywaslimitedtothiazidesonly(OR2.08,95%CI
1.41 to 3.09) and when we excluded patients with an
index year before 1994 (that is, who were included in
our previous publication about antihypertensive drug
therapy; OR 1.95, 95% CI 1.24 to 3.08).
7
Treatment with diuretics plus angiotensin convert-
ingenzymeinhibitorsorangiotensinreceptorblockers
might be associated with a lower risk of myocardial
infarction and stroke than treatment with diuretics
plus β blockers (myocardial infarction: OR 0.76, 95%
CI0.52to1.11;stroke:OR0.71,95%CI0.46to1.10);
however, these associations could well have been the
result of chance (table 2). The difference in stroke risk
between these two regimens was more pronounced
when we limited our analysis to ischaemic strokes
(OR0.56,95%CI0.33to0.96).Additionaladjustment
for pretreatment systolicblood pressure,hypertension
duration,mostrecentsystolicbloodpressure,orsmok-
ing (pack years) altered the relative risk estimates only
minimally.
Table 3showstheresultsofananalysisofdoselevels
for the three treatment groups. Patients receiving
diuretics plus low dose β blockers served as the refer-
ence group. Among patients receiving diuretics plus
calcium channel blockers, the estimated risk of myo-
cardial infarction increased as the dose of the calcium
channel blockers increased (from OR 1.53, 95% CI
0.82 to 2.87 for low dose to OR 2.19, 95% CI 1.12 to
4.27forhighdose).Inpatientstreatedwithangiotensin
converting enzyme inhibitors or angiotensin receptor
blockers, however, the estimated risk of myocardial
infarction decreased as the dose of angiotensin con-
verting enzyme inhibitors or angiotensin receptor
blockers increased (from OR 1.56, 95% CI 0.77 to
3.16 for low dose to OR 0.61, 95% CI 0.34 to 1.10 for
Table 4 |Relative risk of myocardial infarction and stroke in patients receiving various two drug antihypertensive regimens
that included a diuretic*†
Myocardial infarction Stroke
Cases Controls OR (95% CI) Cases Controls OR (95% CI)
Diuretic and atenolol 68 354 Ref 54 354 Ref
Diuretic and verapamil 35 92 2.24 (1.33 to 3.77) 14 92 1.01 (0.50 to 2.02)
Diuretic and felodipine 14 28 2.38 (1.16 to 4.89) 5 28 1.09 (0.36 to 3.33)
Diuretic and lisinopril 46 292 0.81 (0.54 to 1.22) 27 292 0.64 (0.39 to 1.05)
*76% of patients treated with β blockers received atenolol; 52% of patients treated with calcium channel blockers received verapamil and 17%
received felodipine; 91% of patients treated with angiotensin converting enzyme inhibitors or angiotensin receptor blockers received lisinopril.
†Adjusted for age, sex, index year, smoking, and total cholesterol.
Age (years)
  <67
  ≥67
Sex
  Female
  Male
Glucose (mg/dl)
  ≤99
  >99
Pretreatment systolic blood pressure (mm Hg)
  ≤160
  >160
Treated systolic blood pressure (mm Hg)
  ≤140
  >140
Hypertension duration (years)
  ≤10
  >10
2.64 (1.52 to 4.57)
1.53 (0.92 to 2.57)
1.98 (1.15 to 3.38)
1.98 (1.18 to 3.30)
1.91 (1.12 to 3.28)
2.07 (1.22 to 3.50)
2.51 (1.47 to 4.30)
1.60 (0.94 to 2.73)
1.82 (1.08 to 3.05)
2.11 (1.20 to 3.71)
3.42 (2.03 to 5.76)
1.12 (0.63 to 2.00)
36
32
31
37
30
38
35
33
33
35
45
23
0123456
Diuretics and
calcium channel
blockers better
Diuretics and
calcium channel
blockers worse
Odds ratio (95% CI) Odds ratio (95% CI)
Compared with diuretics and β blockers
Cases
77
97
86
88
91
83
86
88
94
80
72
102
Controls
Fig 1 | Relative risk of myocardial infarction in specified subgroups of patients on diuretics and calcium channel blockers, with
diuretics plus β blockers as a reference. Odds ratios adjusted for age, sex, index year, smoking, and total cholesterol
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(table 3).
We repeated our main analysis limited to the most
common drugs in each class used at Group Health
(table 4).Comparedwithuseofdiureticsplusatenolol,
the use of a diuretic with either of the two most com-
monly used calcium channel blockers was associated
with an increase in the risk of myocardial infarction
(OR 2.24, 95% CI 1.33 to 3.77 for verapamil and OR
2.38, 95% CI 1.16 to 4.89 for felodipine). The use of
diuretics plus lisinopril may be associated with a
decreased risk of stroke (OR 0.64, 95% CI 0.39 to
1.05) and with a decreased risk of myocardial infarc-
tion (OR 0.81, 95% CI 0.54 to 1.22), but the 95% con-
fidence interval for both estimates included one.
The figures present the relative risks of myocardial
infarctionandstrokeinsubgroupsdefinedbyage,sex,
serum glucose concentration, pretreatment systolic
blood pressure, treated systolic blood pressure, and
hypertensionduration.Therelativerisk ofmyocardial
infarction associated with the use of diuretics plus cal-
ciumchannelblockerscomparedwiththeuseofdiure-
tics plus β blockers was similar across categories with
the exception of duration of hypertension, where the
associationwaslimitedtothosewithshorterthanmed-
ianduration(P=0.01forthetestforinteraction).Stroke
risk wassimilarin users ofdiuretics pluscalciumchan-
nelblockersandusersofdiureticsplusβblockersinall
of the subgroups. The relative risks of myocardial
infarction and stroke associated with the use of diure-
tics plus angiotensin converting enzyme inhibitors or
angiotensin receptor blockers was also similar across
all subgroups. We would expect on average at least
one false positive for these 24 statistical tests at the
0.05 level.
DISCUSSION
Inthiscase-controlstudyofrelativelylowriskpatients,
treatmentwithdiureticspluscalciumchannelblockers
was associated with a higher risk of myocardial infarc-
tion than treatment with diuretics plus β blockers or
diuretics plus angiotensin converting enzyme inhibi-
tors or angiotensin receptor blockers. This effect was
consistentacrosssubgroupsdefinedbyage,sex,serum
glucose levels, pretreatment blood pressure, and most
recent systolic blood pressure. Treatment with diure-
tics and angiotensin converting enzyme inhibitors or
angiotensin receptor blockers was associated with a
slightly lower risk of myocardial infarction and stroke
than treatment with diuretics and β blockers, but these
associations could have been the result of chance.
Strengths and limitations
The strengths of this study include the use of a popula-
tion based setting, the completeness of case identifica-
tion,thevalidationofcasediagnosis,theascertainment
of a number of potential confounding factors, and the
use of the Group Health pharmacy database to obtain
comparable data on antihypertensive therapy in cases
andcontrols.Allparticipantsweremembersofahealth
maintenance organisation and thus had similar access
tohealthcare.Thesimilaritiesintheclinicalcharacter-
istics of the three treatment groups minimised the
likelihood of important confounding by such
Age (years)
  <67
  ≥67
Sex
  Female
  Male
Glucose (mg/dl)
  ≤99
  >99
Pretreatment systolic blood pressure (mm Hg)
  ≤160
  >160
Treated systolic blood pressure (mm Hg)
  ≤140
  >140
Hypertension duration (years)
  ≤10
  >10
0.74 (0.44 to 1.25)
0.76 (0.44 to 1.30)
0.96 (0.55 to 1.69)
0.62 (0.37 to 1.03)
0.82 (0.48 to 1.41)
0.75 (0.44 to 1.27)
0.80 (0.45 to 1.42)
0.73 (0.44 to 1.22)
0.81 (0.49 to 1.33)
0.69 (0.38 to 1.27)
0.76 (0.45 to 1.29)
0.77 (0.43 to 1.36)
27
23
24
26
25
28
22
28
31
19
28
22
0 0.5 1.0 1.5 2.0
Diuretics and
ACE inhibitors
or ARBs better
Diuretics and
ACE inhibitors
or ARBs worse
Compared with diuretics and β blockers
179
140
139
180
170
149
158
161
199
120
178
141
Odds ratio (95% CI) Odds ratio (95% CI) Cases Controls
Fig 2 | Relative risk of myocardial infarction in specified subgroups of patients on diuretics and angiotensin converting enzyme
(ACE) inhibitors or angiotensin receptor blockers (ARBs), with diuretics plus β blockers as a reference. Odds ratios adjusted for
age, sex, index year, smoking, and total cholesterol
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founding by specific drug therapies for conditions
such as diabetes, heart failure, coronary heart disease,
and chronic kidney disease.
This study was observational, however, and the
patients were not assigned at random to the anti-
hypertensive therapy options. Unknown or unmea-
sured confounding factors might have existed for
which adjustment was not possible. The blood pres-
suremeasurementsweusedinthisstudywereobtained
as part of routine care and are subject to measurement
error; however, any such error would most likely be
non-differential and is unlikely affect our findings.
Measurement error in the assessment or estimation of
other covariatesand theirseverity might have resulted
in incomplete adjustment and residual confounding.
There might also have been residual confounding by
indication owing to the presence of other comorbid
conditions,suchaschronicobstructivepulmonarydis-
ease,thatcouldreducethelikelihoodofapatientbeing
prescribeda βblocker.Thisconfoundingisunlikelyto
be significant in our study given that the proportion of
subjectswhosmokedwassimilarinthethreetreatment
groups (table 1) and that the adjustment for smoking
did not change the relative risk estimates. The partici-
pants in our study were almost 90% white, so our con-
clusions might be limited in their application to other
populations.
Comparison with other studies
Whenadditionalantihypertensivetherapyisneeded,a
patient’s comorbidities may indicate the choice of sec-
ond line treatment.Large long term clinical trials have
identified important major health benefits associated
with β blockers in patients who have coronary
disease
11 or heart failure,
12 and major health benefits
associated withangiotensinconvertingenzyme inhibi-
tors in patients with coronary disease, heart failure,
13
diabetes,
14 and renal failure.
15 However, no trials
have evaluatedthe influence of diuretics accompanied
by different possible second line agents in terms of the
ability of each regimen to prevent myocardial infarc-
tion or stroke.
Severaltrialsoffirstlinetreatmentsforhypertension
have included active treatment comparison groups,
but the trials have generally either compared “old”
drugs with “new” drugs or compared one new drug
with another new drug. Examples include the Inter-
national Verapamil-Trandolapril Study (INVEST)
16;
the Losartan Intervention For Endpoint reduction in
hypertension(LIFE)study
17; the CaptoprilPrevention
Project (CAPPP)
18; the Swedish Trial in Old Patients
withHypertension-2(STOP-2)
19;theAnglo-Scandina-
vian Cardiac Outcomes Trial-Blood Pressure
Lowering Arm (ASCOT-BPLA)
20; and the Valsartan
Antihypertensive Long-term Use Evaluation
(VALUE) trial.
21 Although some of these trials used
diuretics as second line agents, they did not use low
dose diuretics as a first line therapy and often used
the β blocker atenolol as the first line agent.
22
Fewtrialsofcombinationtherapyhaveusedadiure-
ticasthefirstlineantihypertensiveagentinatleastone
arm of the trial. The Hypertension in the Very Elderly
Trial (HYVET) used the diuretic indapamide with or
without perindopril as a first line treatment in patients
aged 80 years or older with hypertension, but the
Age (years)
  <67
  ≥67
Sex
  Female
  Male
Glucose (mg/dl)
  ≤99
  >99
Pretreatment systolic blood pressure (mm Hg)
  ≤160
  >160
Treated systolic blood pressure (mm Hg)
  ≤140
  >140
Hypertension duration (years)
  ≤10
  >10
1.58 (0.61 to 4.07)
0.93 (0.53 to 1.62)
0.98 (0.53 to 1.81)
1.17 (0.52 to 2.63)
1.80 (0.94 to 3.43)
0.53 (0.24 to 1.20)
1.01 (0.46 to 2.25)
1.04 (0.54 to 1.98)
1.14 (0.55 to 2.38)
0.91 (0.46 to 1.76)
0.82 (0.38 to 1.88)
1.37 (0.73 to 2.57)
7
24
20
11
20
11
10
21
13
18
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21
012345
Diuretics and
calcium channel
blockers better
Diuretics and
calcium channel
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Odds ratio (95% CI) Odds ratio (95% CI)
Compared with diuretics and β blockers
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77
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86
88
91
83
86
88
94
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72
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Fig 3 | Relative risk of stroke in specified subgroups of patients on diuretics and calcium channel blockers, with diuretics plus β
blockers as a reference. Odds ratios adjusted for age, sex, index year, smoking, and total cholesterol
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23 In the recently
published Avoiding Cardiovascular Events through
Combination Therapy in Patients Living with Systolic
Hypertension (ACCOMPLISH) trial, high risk
patients with hypertension were randomly assigned to
receive combination therapy with benazepril plus
amlodipine or benazepril plus hydrochlorothiazide.
24
The primary outcome was a composite of cardio-
vascular deaths and cardiovascular events (with the
exception of non-fatal heart failure). Blood pressure
control was similar in both groups. The trial was
stopped early after about three years of follow-up
because the benazepril-amlodipine arm was associated
withareducedriskofcardiovasculardeathsandcardio-
vascular events (HR 0.80, 95% CI 0.72 to 0.90). The
patients in our case-control study differed from those
in the ACCOMPLISH trial in several respects. Amlo-
dipine and benazepril were rarely used as anti-
hypertensive therapies in our study population;
neitherwasthetwodrugcombinationofcalciumchan-
nel blockers plus angiotensin converting enzyme inhi-
bitorsorangiotensinreceptorblockers.Inaddition,the
exclusionsusedtocontrolforpotentialconfoundingby
indication removed most high risk patients from our
study, whereas the ACCOMPLISH trial included
only high risk patients. In clinical trials of anti-
hypertensive treatments, the strategy of selecting high
risk patients who have several additional risk factors is
often used to increase the event rate and the power of
the trial. In observational studies of antihypertensive
treatment, however, the strategy of excluding patients
who have additional indications for specific drug
treatments is the optimal approach to control for con-
founding by indication for those factors.
Possible mechanism
Our findings are consistent with the renin hypothesis,
which suggests that patients’ blood pressure response
to different antihypertensive drugs depends on their
plasma renin levels.
25
Patientsin ourcase-control studygenerallyreceived
atwodrugregimenonlyiftheirbloodpressurewasnot
controlledonsingledrugtherapy,usuallywithadiure-
tic(asodiumandvolumereducingdrug).Patientswith
low renin hypertension would be expected to respond
to a thiazide diuretic alone and would only infre-
quently require a second line drug; therefore, the
pool of patients in our study receiving a two drug regi-
men would be enriched with those who have medium
or high renin hypertension. According to the renin
hypothesis, those patients receiving an additional
anti-renin-system drug—such as an angiotensin con-
verting enzyme inhibitor, an angiotensin receptor
blocker,oraβblocker—wouldbeexpectedtorespond
more favourably in terms of blood pressure control
and reduction in risk of cardiovascular events than
those receiving a different sodium and volume redu-
cing drug—such as a calcium channel blocker. In con-
trast, in the ACCOMPLISH trial, where participants
were randomly assigned to a two drug regimen, we
would expect a mix of high, medium, and low renin
hypertension. This difference in patient populations
could be responsible for the different findings for cal-
cium channel blockers in the two studies.
Age (years)
  <67
  ≥67
Sex
  Female
  Male
Glucose (mg/dl)
  ≤99
  >99
Pretreatment systolic blood pressure (mm Hg)
  ≤160
  >160
Treated systolic blood pressure (mm Hg)
  ≤140
  >140
Hypertension duration (years)
  ≤10
  >10
1.32 (0.64 to 2.74)
0.55 (0.31 to 0.97)
0.55 (0.30 to 1.01)
1.00 (0.51 to 1.97)
1.13 (0.60 to 2.12)
0.45 (0.23 to 0.89)
0.69 (0.31 to 1.55)
0.74 (0.43 to 1.28)
0.67 (0.36 to 1.28)
0.70 (0.37 to 1.34)
0.68 (0.37 to 1.25)
0.75 (0.38 to 1.51)
15
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16
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13
11
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Compared with diuretics and β blockers
179
140
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Odds ratio (95% CI) Odds ratio (95% CI) Cases Controls
Fig 4 | Relative risk of stroke in specified subgroups of patients on diuretics and angiotensin converting enzyme (ACE)
inhibitors or angiotensin receptor blockers (ARBs), with diuretics plus β blockers as a reference. Odds ratios adjusted for age,
sex, index year, smoking, and total cholesterol
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pressure rather than the type of treatment is the major
determinant of the risk of cardiovascular complica-
tions in patientswith hypertension.
161821 This perspec-
tiveimpliesthatthe mostimportantaimoffuturetrials
would be to evaluate the association between aggres-
sive blood pressure control and future health
outcomes.
2627 From a clinical pharmacology point of
view, however, it is unlikely that the major anti-
hypertensive drug classes, with their various different
targets and mechanisms of action, all have the same
effect on the risks of myocardial infarction, stroke,
and heart failure. For instance, in ALLHAT, patients
initially randomly assigned to doxazosin had a higher
risk of heartfailure than those randomised to the other
three treatment strategies despite achieving a similar
reduction in blood pressure, and the doxazosin arm
was stopped early.
28 The ACCOMPLISH trial pro-
vides additional evidence in this regard.
23 Such data
suggest the need to consider the use of more than one
strategy of blood pressure lowering in ongoing studies
such as the Systolic Blood Pressure Intervention Trial
(SPRINT).
29
Conclusions and implications
Thegoaloftreatinghypertensionistopreventcompli-
cations associated with high blood pressure. In this
case-control study of relatively low risk patients, the
use of diuretics plus calcium channel blockers was
associated with a higher risk of myocardial infarction
than the use of diuretics plus β blockers or diuretics
plus angiotensin converting enzyme inhibitors or
angiotensin receptor blockers. These findings support
the National Institute for Health and Clinical Excel-
lence guidelines, which do not recommend the use of
diuretics plus calcium channel blockers. A large long
term trial of second line treatments in patients who are
already on a low dose diuretic—as recommended by
theNationalHeart,Lung,andBloodInstituteworking
group
7—would be required to provide a solid basis for
treatment recommendations.
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